Supportive secondary endpoints
WI-NRS reduction, pruritus

Proportion of patients with WI-NRS reduction ≥4 over time until week 24Proportion of patients with WI-NRS reduction ≥4 at week 4Proportion of patients with IGA PN-S 0 or 1 score at week 12Proportion of patients with IGA PN-S 0 or 1 score at week 8Proportion of patients with IGA PN-S 0 or 1 score at week 4Proportion of patients with IGA PN-A (PN activity) 0 or 1 score at week 24Proportion of patients with IGA PN-A 0 or 1 score at week 12Proportion of patients with IGA PN-A 0 or 1 score at week 8Proportion of patients with IGA PN-A 0 or 1 score at week 4Time to onset of effect on pruritus as measured by proportion of patients with an improvement (reduction) in WI-NRS by ≥4 from baseline during the 24-week treatment periodChange from baseline in WI-NRS at week 24Change from baseline in WI-NRS at week 12Percent change from baseline in WI-NRS at week 12Percent change from baseline in WI-NRS at week 4Percent change from baseline in WI-NRS at week 2Percent change from baseline in WI-NRS over time until week 24Onset of action in change from baseline in WI-NRS (first Change from baseline in IGA PN-S score at week 24Change from baseline in IGA PN-S score at week 12Change from baseline in IGA PN-S score at week 8Change from baseline in IGA PN-S score at week 4Change from baseline in health-related QoL, as measured by DLQI to week 12